SAN DIEGO—(BUSINESS WIRE)—Jan. 11, 2016—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system (CNS)disorders, today announced Jim Daly has joined its Board of Directors.Mr. Daly is a biopharmaceutical executive with 30 years of experienceleading U.S. and global businesses.
“Jim brings extensive commercial experience to our Board as we continueour transition to an integrated pharmaceutical company,” said Leslie L.Iversen, Ph.D., Chairman of ACADIA’s Board of Directors. “Over thecourse of his career, Jim has successfully launched and commercializedmajor products in multiple therapeutic areas and built market-leadingglobal franchises. His deep knowledge and expertise are welcome as wedeliver on our vision of building a leading CNS company dedicated toimproving the lives of patients through innovative medicines.”
Mr. Daly previously served as Executive Vice President and ChiefCommercial Officer at Incyte Corporation from 2012 to 2015. During histenure, he was instrumental in re-accelerating the launch of Jakafi®and driving sustained growth. Prior to joining Incyte, Mr. Daly workedfor Amgen, Inc. for ten years, holding multiple leadership positions. Inhis last role, Mr. Daly served as Senior Vice President, North AmericaCommercial Operations, Global Marketing and Commercial Development.Previously, he served as Vice President and General Manager of Amgen’sOncology Business Unit. His teams at Amgen were responsible for thesuccessful launch of many products, including Aranesp®,Neulasta®, Vectibix®, Nplate®, Xgeva®and Prolia®.
Previously, Mr. Daly spent over 16 years with GlaxoWellcome/GlaxoSmithKline (GSK) where he held roles of increasingresponsibility, including Senior Vice President, General Manager,Respiratory and Anti-Infective Business Unit, and led the U.S. launch ofAdvair®. He currently serves on the Board of Directors ofChimerix Inc. Mr. Daly earned his B.S. in Pharmacy and M.B.A. from theUniversity at Buffalo, The State University of New York.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA has a pipeline of productcandidates led by NUPLAZID™ (pimavanserin), for which we have submitteda New Drug Application (NDA) in Parkinson’s disease psychosis to the FDAand which has the potential to be the first drug approved in the UnitedStates for this condition. The FDA has classified the NUPLAZID NDA ashaving Priority Review status. Pimavanserin is also in Phase IIdevelopment for Alzheimer’s disease psychosis and has successfullycompleted a Phase II trial in schizophrenia. ACADIA also hasclinical-stage programs for glaucoma and, in collaboration withAllergan, Inc., for chronic pain. ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the potential for NUPLAZID(pimavanserin) to be the first drug approved in the United States forParkinson’s disease psychosis (PDP) and the potential timing of suchapproval, if approved at all, by the FDA; the benefits to ACADIA of Mr.Daly joining its Board of Directors; the progress, timing and results ofACADIA’s drug discovery and development programs, either alone or with apartner, including the progress and expected timing of clinical trials;and the benefits to be derived from ACADIA’s product candidates,including pimavanserin. These statements are only predictions based oncurrent information and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingthe risks and uncertainties inherent in drug discovery, development,approval and commercialization, and collaborations with others, and thefact that past results of clinical trials and past regulatory decisionsmay not be indicative of future trial results or future regulatorydecisions, respectively. For a discussion of these and other factors,please refer to ACADIA’s annual report on Form 10-K for the year endedDecember 31, 2014 as well as ACADIA’s subsequent filings with theSecurities and Exchange Commission. You are cautioned not to place unduereliance on these forward-looking statements, which speak only as of thedate hereof. This caution is made under the safe harbor provisions ofthe Private Securities Litigation Reform Act of 1995. Allforward-looking statements are qualified in their entirety by thiscautionary statement and ACADIA undertakes no obligation to revise orupdate this press release to reflect events or circumstances after thedate hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, 858-558-2871
Directorof Investor Relations